US FDA Puts Mirati’s KRAS Challenge To Amgen In The Slow Lane
Regulator's Decision Slated For December 2022
The US regulator will review adagrasib on standard timelines, leaving some investors anxious about Mirati’s efforts to rival Amgen’s Lumakras.
